ReviewFrontiers in immunology2026
The plasticity and metabolic reprogramming of macrophage in ulcerative colitis.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Macrophages exhibit phenotypic plasticity, which plays a role in driving tissue injury and promoting mucosal repair in ulcerative colitis (UC). Intestinal macrophages originate from both embryo-derived resident cells and circulating monocytes. Macrophage polarization influences inflammatory responses and is regulated by cytokines, chemokines, growth factors, and adhesion molecules. Tissue-specific metabolic reprogramming governs macrophage plasticity. Glucose metabolic reprogramming drives M1-like polarization. During glycolysis, mitochondria influence reactive oxygen species (ROS) production which alters the fate of macrophages in UC. Moreover, the communication of cell to cell can also regulate macrophage plasticity. Transcriptomics, proteomics, and single-cell sequencing can be employed to dissect the phenotypes and heterogeneity of macrophage polarization. Numerous clinical trials suggest that regulating macrophage polarization, inhibiting excessive activation of macrophages, blocking the abnormal recruitment of macrophages to intestinal inflammatory sites, macrophage-directed cell therapy, and combination therapy can effectively treat patients with UC. Indeed, the macrophage polarization is characterized by ROS, microbial community and bacterial products in inflammation of the colonic mucosa which is regulated by metabolic programming of macrophages. Indeed, macrophage polarization is characterized by ROS, microbial community, and bacterial products in the inflamed colonic mucosa. The macrophage polarization process is tightly regulated by the metabolic programming. In summary, this review analyzes macrophage plasticity and functional diversity, as well as the metabolic reprogramming and microenvironmental signals that shape macrophage polarization, and offers new insights for macrophage-based clinical interventions in UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.